Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$40.78M$40.78Mderived+19.1% vs Q4 2023 Net Income$3.66M$3.66MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$30,553,000+25.5% Operating Incomederived$4,173,000N/M Operating Cash Flowderived-$11,780,000N/M Free Cash Flowderived-$12,418,000N/M Margins · derivedGross margin74.9%+3.8 pt vs Q4 2023
Operating margin10.2%+40.1 pt vs Q4 2023
Net margin9.0%+40.3 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 27, 2025 · 58 d after period end